Roy Fleischmann, EULAR 2021: The Open-label Extension of the SELECT-COMPARE Study

TouchIMMUNOLOGY were delighted to talk with Professor Roy Fleischmann (The University of Texas Southwestern Medical Center and The Metroplex Clinical Research Center, Dallas, TX, US) around the 3 year results from the open-label extension study of upadacitinib or adalimumab in patients with rheumatoid arthritis.

‘Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 years From the SELECT-COMPARE Study.’ (POS0087), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.

Questions

1. What have we learned from the SELECT-COMPARE study about the efficacy and safety of upadacitinib and adalimumab in patients with rheumatoid arthritis with inadequate response to methotrexate? (0:19)
2. Could you tell us a little about the open-label extension study? (2:21)
3. What have been the efficacy and safety findings at 3 years, and how do they compare to previous analyses? (4:35)
4. Which safety signals are of particular concern, and what are their implications for the future use of TNF inhibitors? (6:25)
5. What questions remain unanswered, and what future analyses are planned? (7:57)

Disclosures: Roy Fleischmann discloses being a consultant for AbbVie.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.

Filmed as a highlight of EULAR 2021 (Virtual).